Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Xilio Therapeutics, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 28 | 32 | +4 |
| Shares | 15.9M | 16.1M | +145.5K (+0.9%) |
| Value | $42.8M | $51.0M | +$8.14M (+19.0%) |
New holders (4)
Institutions that held Xilio Therapeutics, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 71,635 | $227.8K | 0.00% |
| Dimensional Fund Advisors LP | 17,881 | $56.9K | 0.00% |
| Key Financial Inc | 830 | $2.63K | 0.00% |
| Royal Bank of Canada | 731 | $2.00K | 0.00% |
Sold out (0)
Institutions that held Xilio Therapeutics, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
None.